These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5571114)

  • 21. A simple and rapid gas chromatography for determining 3,4-dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid in urine from patients with parkinsonism treated with L-3,4-dihydroxyphenylalanine.
    Fukaya J; Imai K; Tamura Z
    Clin Chim Acta; 1971 Jul; 33(2):470-2. PubMed ID: 5119325
    [No Abstract]   [Full Text] [Related]  

  • 22. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 23. Predicting response to levodopa.
    Lakke JP; Korf J; van Praag HM
    Lancet; 1971 Jul; 2(7716):164-5. PubMed ID: 4104491
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 26. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 27. Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.
    Garelis E; Young SN; Lal S; Sourkes TL
    Brain Res; 1974 Oct; 79(1):1-8. PubMed ID: 4279131
    [No Abstract]   [Full Text] [Related]  

  • 28. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
    Weiner WJ; Klawans HL
    J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

  • 30. Determination of 3-methoxy-4-hydroxyphenylethylene glycol, a noradrenaline metabolite, in cerebrospinal fluid and urine.
    O'Keeffe R; Brooksbank BW
    Clin Chem; 1973 Sep; 19(9):1031-5. PubMed ID: 4744804
    [No Abstract]   [Full Text] [Related]  

  • 31. Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment.
    Van Sande M; Caers J; Lowenthal A
    Z Neurol; 1971 Apr; 199(1):24-9. PubMed ID: 4102746
    [No Abstract]   [Full Text] [Related]  

  • 32. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 33. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 35. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 36. A study of spinal fluid homovanillic acid (HVA) in patients with diseases of the nervous system.
    Mones RJ; Wilk S; Green J; Jutkowitz R
    Mt Sinai J Med; 1972; 39(5):478-85. PubMed ID: 4538762
    [No Abstract]   [Full Text] [Related]  

  • 37. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 38. [Biochemistry of depression].
    Matussek N
    J Neural Transm; 1972; 33(3):223-34. PubMed ID: 4565920
    [No Abstract]   [Full Text] [Related]  

  • 39. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.